Sumatriptan can inhibit trigeminal afferents by an exclusively neural mechanism

Brain

Volumn 119, Issue 5, 1996, Pages 1419-1428

  Hoskin, Karen L ^a   Kaube, Holger ^b   Goadsby, Peter J ^a,c  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cerebrovascular; Headache; Migraine; Serotonin; Vascular pain

Indexed keywords

ANTIMIGRAINE AGENT; CARBON DIOXIDE; CHLORALOSE; SUMATRIPTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE MONITORING; BRAIN BLOOD VESSEL; CAT; CERVICAL SPINAL CORD; CONTROLLED STUDY; DRUG EFFICACY; DURA MATER; ELECTROSTIMULATION; HEART RATE; IMMEDIATE EARLY GENE; IMMUNOHISTOCHEMISTRY; MECHANICAL STIMULATION; MIGRAINE; NERVE CONDUCTION; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; RECTUM TEMPERATURE; SENSORY NERVE; SINUS VENOSUS; SPINAL CORD DORSAL HORN; SUPERIOR SAGITTAL SINUS; TEMPORALIS MUSCLE; TRIGEMINAL NERVE; TRIGEMINAL NUCLEUS; VASOCONSTRICTION;

AFFERENT PATHWAYS; ANIMALS; CATS; ELECTRIC STIMULATION; MIGRAINE DISORDERS; PROTO-ONCOGENE PROTEINS C-FOS; SUMATRIPTAN; TRIGEMINAL NERVE;

EID: 0029907006     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/119.5.1419     Document Type: Article

References (64)

1. 1D-like receptors, and a comparison with grafted veins. Naunyn Schmiedebergs Arch Pharmacol 1992; 345: 500-8.
2. Berman AN. The brain stem of the cat. A cytoarchitectonic atlas with stereotaxic co-ordinates. Madison: University of Wisconsin Press, 1968.
3. Buzzi MG, Moskowitz MA. The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol 1990; 99: 202-6.
4. Buzzi MG, Carter WB, Shimizu T, Heath H, Moskowitz MA. Dihydroergotamine and sumatriptan attenuate levels of calcitonin gene-related peptide in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion. Neuropharmacology 1991; 30: 1193-200.
5. 1D antagonists. J Med Chem 1994; 37: 2253-7.
6. Fanciullacci M, Alessandri M, Figini M, Geppetti P, Michelacci S. Increase in plasma calcitonin generelated peptide from the extracerebral circulation during nitroglycerin-induced cluster headache attack. Pain 1995; 60: 119-23.
7. Feindel W, Penfield W, McNaughton F. The tentorial nerves and localization of intracranial pain in man. Neurology 1960; 10: 555-63.
8. Gallai V, Sarchielli P, Floridi A, Franceschini M, Codini M, Glioti G, et al. Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia 1995; 15: 384-90.
9. Goadsby PJ. The challenge of headache for the 1990s. Curr Opin Neurol 1994; 7: 255-7.
10. Goadsby PJ, Duckworth JW. Effect of stimulation of trigeminal ganglion on regional cerebral blood flow in cats. Am J Physiol 1987; 253: R270-4.
11. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993; 33: 48-56.
12. Goadsby PJ, Edvinsson L. Human in vivo evidence for trigeminovascular activation in cluster headache. Brain 1994; 117: 427-34.
13. Goadsby PJ, Hoskin KL. Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)-1-D receptor agonist zolmitriptan (311C90): are brain stem sites a therapeutic target in migraine? Pain 1996. In press.
14. Goadsby PJ, Zagami AS. Stimulation of the superior sagittal sinus increases metabolic activity and blood flow in certain regions of the brainstem and upper cervical spinal cord of the cat. Brain 1991; 114: 1001-11.
15. Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol 1988; 23: 193-6.
16. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990; 28: 183-7.
17. Goadsby PJ, Zagami AS, Lambert GA. Neural processing of craniovascular pain: a synthesis of the central structures involved in migraine. Headache 1991a; 31: 365-71.
18. Goadsby PJ, Zagami AS, Donnan GA, Symington G, Anthony M, Bladin PF, et al. Oral sumatriptan in acute migraine. Lancet 1991b; 338: 782-3.
19. 1D binding sites. Br J Pharmacol 1991; 102: 227-33.
20. Hammond DL, Presley R, Gogas KR, Basbaum AI. Morphine or U-50, 488 suppresses Fos protein-like immunoreactivity in the spinal cord and nucleus tractus solitarii evoked by a noxious visceral stimulus in the rat. J Comp Neurol 1992; 315: 244-53.
21. Hartig PR, Hoyer D, Humphrey PPA, Martin GR. Alignment of receptor nomenclature with the humam genome: classification of 5HT-1B and 5-HT1D receptor subtypes. Trends Pharmacol Sci 1996; 17: 103-5.
22. Hoskin KL, Kaube H, Goadsby PJ. Mechanical distension of the superior sagittal sinus evokes c-Fos expression in trigeminal neurons-towards a better model of migraine [abstract]. Cephalalgia 1995; 15 Suppl 14: 104.
23. Hoskin KL, Kaube H, Goadsby PJ. Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine: a c-Fos and electrophysiological study. Brain 1996; 119: 249-56.
24. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane FJ, et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). [Review]. Pharmacol Rev 1994; 46: 157-203.
25. Humphrey PPA, Goadsby PJ. The mode of action of sumatriptan is vascular? A debate. [Review]. Cephalalgia 1994; 14: 401-10.
26. Humphrey PPA, Feniuk W, Marriott AS, Tanner RJN, Jackson MR, Tucker ML. Preclinical studies on the anti-migraine drug, sumatriptan. [Review]. Eur Neurol 1991; 31: 282-90.
27. Kaube H, Hoskin KL, Goadsby PJ. Activation of the trigeminovascular system by mechanical distension of the superior sagittal sinus in the cat [see comments]. Cephalalgia 1992; 12: 133-6, Comment in: Cephalalgia 1992; 12: 127.
28. Kaube H, Hoskin KL, Goadsby PJ. Activation of the trigeminovascular system by mechanical distension of the superior sagittal sinus in the cat [see comments]. Cephalalgia 1992; 12: 133-6, Comment in: Cephalalgia 1992; 12: 127.
29. Kaube H, Hoskin KL, Goadsby PJ. Inhibition by sumatriptan of central trigeminal neurones only after blood-brain barrier disruption. Br J Pharmacol 1993a; 109: 788-92.
30. Kaube H, Keay KA, Hoskin KL, Bandler R, Goadsby PJ. Expression of c-Fos-like immunoreactivity in the caudal medulla and upper cervical spinal cord following stimulation of the superior sagittal sinus in the cat. Brain Res 1993b; 629: 95-102.
31. Keller JT, Marfurt CF. Peptidergic and serotoninergic innervation of the rat dura mater. J Comp Neurol 1991; 309: 515-34.
32. Keller JT, Saunders MC, Beduk A, Jollis JG. Innervation of the posterior fossa dura of the cat. Brain Res Bull 1985; 14: 97-102.
33. Kimmel DL. The nerves of the cranial dura mater and their significance in durai headache and referred pain. Clin Med School Q 1961; 22: 16-26.
34. Lambert GA, Goadsby PJ, Zagami AS, Duckworth JW. Comparative effects of stimulation of the trigeminal ganglion and the superior sagittal sinus on cerebral blood flow and evoked potentials in the cat. Brain Res 1988; 453: 143-9.
35. Lance JW. Mechanism and management of headache. 5th ed. London: Butterworth-Heinemann, 1993.
36. Lee WS, Moskowitz MA. Conformationally restricted sumatriptan analogues, CP-122,288 and CP-122,638 exhibit enhanced potency against neurogenic inflammation in dura mater. Brain Res 1993; 626: 303-5.
37. Liu-Chen LY, Mayberg MR, Moskowitz MA. Immunohistochemical evidence for a substance P-containing trigeminovascular pathway to pial arteries in cats. Brain Res 1983; 268: 162-6.
38. Martins IP, Baeta E, Paiva T, Campos J, Gomes L. Headaches during intracranial endovascular procedures: a possible model of vascular headache. Headache 1993; 33: 227-33.
39. McNaughton FL. The innervation of the intracranial blood vessels and the durai sinuses. In: Cobb S, Frantz AM, Penfield W, Riley HA, editors. The circulation of the brain and spinal cord. New York: Hafner Publishing, 1966: 178-200.
40. McNaughton FL, Feindel WH. Innervation of intracranial structures: a reappraisal. In: Rose FC, editor. Physiological aspects of clinical neurology. Oxford: Blackwell Scientific, 1977: 279-93.
41. Moskowitz MA. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. [Review]. Trends Pharmacol Sci 1992; 13: 307-11.
42. Nozaki K, Moskowitz MA, Boccalini P. CP-93,129, sumatriptan, dihydroergotamine block c-fos expression within rat trigeminal nucleus caudalis caused by chemical stimulation of the meninges. Br J Pharmacol 1992; 106: 409-15.
43. O'Shaughnessy CT, Connor HE, Feniuk W. Extracellular recordings of membrane potential from guinea-pig isolated trigeminal ganglion: lack of effect of sumatriptan. Cephalalgia 1993; 13: 175-9.
44. 1Dα receptor sites. Neuropharmacology 1995; 34: 235-7.
45. Penfield W, McNaughton FL. Dural headache and innervation of the dura mater. Arch Neurol Psychiatry 1940; 44: 43-75.
46. 1D binding sites. Eur J Pharmacol 1989; 163: 133-6.
47. 1D subtype. Br J Pharmacol 1991; 102: 191-7.
48. Ray BS, Wolff HG. Experimental studies on headache. Pain sensitive structures of the head and their significance in headache. Arch Surg 1940; 41: 813-56.
49. Rebeck GW, Maynard KI, Hyman BT, Moskowitz MA. Selective 5-HT1D alpha serotonin receptor gene expression in trigeminal ganglia: implications for antimigraine drug development. Proc Natl Acad Sci USA 1994; 91: 3666-9.
50. Rexed B. A cytoarchitectonic atlas of the spinal cord in the cat. J Comp Neurol 1954; 96: 297-380.
51. Saxena PR. 5-HT in migraine - an introduction.[Review]. J Neurol 1991; 238 Suppl 1: S36-7.
52. Schoeffter P, Hoyer D. How selective is GR 43175? Interactions with functional 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol 1989; 340: 135-8.
53. 1D receptor subtype is negatively coupled to adenylate cyclase in calf substantia nigra. Naunyn Schmiedebergs Arch Pharmacol 1988; 337: 602-8.
54. Shepheard SL, Williamson DJ, Williams J, Hill RG, Hargreaves RJ. Comparison of the effects of sumatriptan and the NK1 antagonist CP-99,994 on plasma extravasation in the dura mater and c-fos mRNA expression in the trigeminal nucleus caudalis of rats. Neuropharmacology 1995; 34: 255-61.
55. Siegel S. Non-parametric statistics for the behavioral sciences. New York: McGraw-Hill, 1956.
56. Steiger HJ, Tew JM, Keller JT. The sensory representation of the dura mater in the trigeminal ganglion of the cat. Neurosci Lett 1982; 31: 231-6.
57. Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med 1991; 325: 316-21.
58. Tran Dinh YR, Thurel C, Cunin G, Serrie A, Seylaz J. Cerebral vasodilation after the thermocoagulation of the trigeminal ganglion in humans. Neurosurgery 1992; 31: 658-62.
59. Villalon CM, Bom AH, Den Boer MO, Heiligers JP, Saxena PR. Effects of S9977 and dihydroergotamine in an animal experimental model for migraine. Pharmacol Res 1992; 25: 125-37.
60. 1D recognition sites: radioligand binding studies in human, pig and calf brain membranes. Naunyn Schmiedebergs Arch Pharmacol 1988; 337: 595-601.
61. Weiller C, May A, Limmroth V, Jüptner M, Kaube H, Schayck RV, Coenen HH, Diener HC. Brain stem activation in spontaneous human migraine attacks. Nat Med 1995; 1: 658-60.
62. 1Dβ. Proc Natl Acad Sci USA 1992; 89: 3630-4.
63. Wolff HG. Headache and other head pain. 2nd ed. New York: Oxford University Press, 1963.
64. Zagami AS, Goadsby PJ, Edvinsson L. Stimulation of the superior sagittal sinus in the cat causes release of vasoactive peptides. Neuropeptides 1990; 16: 69-75.